Cometriq / cabozantinib / XL184 approved for a thyroid cancer

>

Prostate Cancer

✚ New Topic ✚ Reply

RobertC

Veteran Member

Joined : May 2011

Posts : 1336

Posted Yesterday 2:50 PM (GMT 0)

www.medicalnewstoday.com/articles/253401.php

Cometriq (cabozantinib) / XL184 / cabo has been approved by the FDA for the treatment of progressive medullary thyroid cancer that has metastasized. Is in Phase III plus other trials for prostate cancer. (especially bone mets.)

Post Edited (robertC) : 11/30/2012 8:05:54 AM (GMT-7)

PeterDisAbelard.

Forum Moderator

Joined : Jul 2012

Posts : 6432

Posted Yesterday 3:05 PM (GMT 0)

The article said...
27% of those in the placebo group experienced tumor reductions which lasted an average of almost 15 months

None of the participants in the placebo group experienced tumor reduction

A typo, surely.

RobertC

Veteran Member

Joined : May 2011

Posts : 1336

Posted Yesterday 3:11 PM (GMT 0)

Yes, that's a typo in the article.

✚ New Topic ✚ Reply